|1.||Prostatic Neoplasms (Prostate Cancer)
12/01/1999 - "Subcutaneous depot formulations of avorelin were well tolerated and had protracted inhibitory effects on pituitary gonadotropin secretion in patients with prostate cancer. "
12/01/1999 - "We evaluate the pharmacodynamics, pharmacokinetics and tolerability of a sustained release depot formulation of avorelin, a new potent super agonist of luteinizing hormone-releasing hormone receptors, in patients with prostate cancer. "
12/01/1999 - "Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. "
|1.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)